Users Stopping Anti-Obesity Jabs Regain Weight Four Times Faster Than Dieters

A recent study indicates that patients who discontinue popular weight-loss injections like semaglutide or tirzepatide may regain shed pounds much more quickly than those who halt traditional lifestyle regimens.

Published data in a major medical journal demonstrates that while overweight people often shed a large proportion of their body weight while using the jabs, the mass comes back at an estimated rate of 0.8 kg per month after stopping.

"Users purchasing these drugs must be cognizant of the danger of rapid rebound weight gain when the therapy ends," cautioned researcher Dr. Susan Jebb.

This pace of recovery suggests a return to pre-treatment mass in about one and a half years.

Analyzing Treatments

The analysis, which examined dozens of studies involving thousands of patients, compared the results of these new drugs with other pills.

The team point out that people who lose weight through diet and exercise usually experience a slower weight regain—around 0.1 kg a month—once they finish.

Explaining the Quick Regain

Doctors suggest the mode of action of the jabs accounts for the accelerated rebound.

GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which moderates hunger.

"Long-term administration of the hormone levels several times higher than normal could lead to the system to generate a reduced amount of its own natural GLP-1, and may also reduce sensitivity to its effects," said Dr. Adam Collins, a nutrition researcher.

"Withdrawal of this hormone supplement means hunger is uncontrolled, making excessive eating much more probable."

An Ongoing Disease?

The NHS advise the injections for individuals with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.

Many experts argue that, considering the likelihood of weight regain, the treatment might need to be life-long.

This view is echoed by pharmaceutical companies, who state that the results "underscore the chronic character of excess weight," akin to managing diseases like diabetes.

Patient Testimonies

Users who have come off the jabs explain a intense resurgence of cravings.

"It was like a trigger that goes on and I was suddenly ravenous," recalled one woman.

This difficulty is worsened if individuals have not adopted lasting dietary or behavioural modifications during treatment.

Widespread Interest

Survey data suggest that millions of people in the UK have used weight-loss jabs in the last 12 months, with desire continuing to grow.

• Adoption is more common among females compared to males.
• The middle-aged demographic shows the greatest level of interest.
• A large proportion access the drugs through private healthcare rather than public health services.

Finally, clinicians stress that while the jabs are potent tools for shedding pounds, they are not a permanent fix and long-term success likely depends on combined lifestyle support.